- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07237594
Bloqueo de IL-17 para Reducir irAEs (REPLAY) (REPLAY)
Un estudio de factibilidad que utiliza el bloqueo de IL-17 para disminuir el riesgo de eventos adversos relacionados con la inmunidad
The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Participants will receive pre-treatment (pre-ICI) with secukinumab (300mg) within 1 to 7 days prior to the initial ICI dose. Participants will then resume ICI therapy (the specific ICI agent and dose are determined by the treating physician per their standard practice). Participants will receive secukinumab weekly for the first 4 weeks, and then once every 4 weeks thereafter until grade 3 side effect occurs or ICI is discontinued.
Participants will have AE (adverse event) assessments at each study visit. Disease assessments via CT scans will be performed every 12 weeks with iRECIST/RECIST. Research blood samples and tumor tissue will be collected. All participants will be followed by phone call or medical record review for survival for up to three years. Participants who come off for reasons other than disease progression will also be followed with CT scans every 12 weeks until progression for up to two years.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Emily Bolch
- Correo electrónico: emily.bolch@duke.edu
Copia de seguridad de contactos de estudio
- Nombre: April Salama, MD
- Número de teléfono: +1 919 681 9507
- Correo electrónico: april.salama@duke.edu
Ubicaciones de estudio
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University Health System
-
Contacto:
- April Salama, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
-
Histologically confirmed advanced metastatic melanoma
-
Participants of any gender who are at least 18 years of age on the day of signing informed consent
-
Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti LAG3 or PD-1 plus anti CTLA-4 therapy as standard of care. Patients should either be restarting the same ICI regimen which contributed to the prior toxicity or have a clinical need to escalate to doublet (combination) ICI therapy, plan for therapy should be reviewed by the PI of this study.
-
Participant (or legally acceptable representative if applicable) provides written informed consent for the trial
-
Participant must have had prior treatment with ICI therapy (either PD-1 therapy or PD-1 plus anti LAG3 or PD-1 plus anti CTLA-4 therapy as standard of care) and experienced grade 2 or higher immune-related colitis, hepatitis, or skin rash leading to treatment interruption or discontinuation or requiring steroid administration (systemic or topical).
- Note that patients who experience more than one irAEs are eligible to participate
-
Adequate organ function as defined below. Standard of care labs drawn within 42 days prior to consent may be used for the purposes of determining eligibility.
- Absolute Neutrophil Count (ANC) ≥ 1500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin* ≥ 9.0 g/dL or ≥ 5.6 mmol/L *Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the previous 2 weeks
- AST/ALT 2.5x upper limit of normal
Exclusion Criteria:
-
Uveal melanoma
-
Any participants known to be pregnant or breastfeeding.
-
Known diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent), or any other form of immunosuppressive therapy within 7 days prior to first research biopsy
-
Patients with symptomatic CNS metastases and/or carcinomatous meningitis
- Patients with asymptomatic, clinically stable CNS metastases are allowed provided they do not require steroid treatment
-
History of or active (non-infectious) pneumonitis that required steroids
-
Active infection requiring systemic therapy
-
Known history of Human Immunodeficiency Virus (HIV) infection
-
Known history of Hepatitis B or known active Hepatitis C virus infection. NOTE: no testing for Hepatitis B or Hepatitis C is required
-
Known history of active TB (Bacillus Tuberculosis)
-
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with subject's participation for the full duration of the study, or make it not in the best interest of the subject to participate, in the opinion of the treating physician
-
Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
-
History of allogenic tissue or solid organ transplant
-
History of active autoimmune disease requiring systemic therapy within the past 12 months, with the exception of ICI induced irAEs.
-
Has not been treated with secukinumab within the last 12 months
-
History of prior cardiac, neurologic, ocular IRAE related to ICI; history of blistering cutaneous IRAE related to ICI
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Secukinumab
Participants will first undergo pre-treatment with secukinumab (300mg subcutaneously) within 1 to 7 days prior to resumption of ICI treatment. Participants will then undergo anti-PD-1 therapy, anti PD-1 plus anti LAG3 (relatlimab) or anti-PD-1 plus anti CTLA-4 therapy at the discretion of their treating physician. Participants will concurrently receive secukinumab 300mg subcutaneously weekly for the first 4 weeks of treatment and then every 4 weeks. |
Secukinumab 300mg subcutaneously |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety of administering an IL-17A (human IgG1κ) monoclonal antibody (secukinumab) as determined by occurrence of immune-related Adverse Events (irAEs)
Periodo de tiempo: Until grade 3 side effect occurs or three years, whichever comes first
|
Participants will be assessed for AEs at each study visit. AEs are graded by NCI-CTCAE v5.0 criteria. |
Until grade 3 side effect occurs or three years, whichever comes first
|
|
Feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody (secukinumab) as determined by occurrence of immune-related Adverse Events (irAEs)
Periodo de tiempo: Until grade 3 side effect occurs or three years, whichever comes first
|
Participants will be assessed for AEs at each study visit. AEs are graded by NCI-CTCAE v5.0 criteria. |
Until grade 3 side effect occurs or three years, whichever comes first
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: April Salama, MD, Duke University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Enfermedades de la piel
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Neoplasias De La Piel
- Enfermedades de la piel y del tejido conectivo
- Melanoma
- secukinumab
Otros números de identificación del estudio
- Pro00118701
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .